The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids

Medical Journal of Australia

Volumn 199, Issue 10, 2013, Pages 696-699

  Nielsen, Suzanne ^a   Bruno, Raimondo ^b   Degenhardt, Louisa ^c   Stoove, Mark A ^d,e   Fischer, Jane A ^f   Carruthers, Susan J ^g   Lintzeris, Nicholas ^a,h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d BURNET INSTITUTE   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f FLINDERS UNIVERSITY   (Australia)

^g CURTIN UNIVERSITY   (Australia)

^h SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE PLUS NALOXONE; DIAZEPAM; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; OXAZEPAM; OXYCODONE;

ADULT; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG MISUSE; DRUG USE; FORGERY; HUMAN; MEDICAL SERVICE; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PRESCRIPTION; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; TREATMENT DURATION; TREATMENT INDICATION;

EID: 84952265023     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.11331     Document Type: Article

References (24)

1. Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 2009; 39: 676-681.
2. Rintoul AC, Dobbin MDH, Drummer OH, Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000-09. Inj Prev 2010; 17: 254-259.
3. Executive Office of the President of the United States. Epidemic: responding to America's prescription drug abuse crisis. 2011. http://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf (accessed Aug 2012).
4. Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev 2011; 30: 264-270.
5. Nielsen S, Dietze P, Lee N, et al. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction 2007; 102: 616-622.
6. Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007; 90: 64-71.
7. Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev 2005; 24: 411-418.
8. Lintzeris N, Nielsen S. Benzodiazepines, methadone, buprenorphine: interactions and clinical management. Am J Addict 2010; 19: 59-72.
9. Brands B, Blake J, Marsh DC, et al. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis 2008; 27: 37-48.
10. Darke S, Hall W, Ross M, Wodak A. Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. Drug Alcohol Depend 1992; 31: 31-36.
11. Brands B, Blake J, Sproule B, et al. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend 2004; 73: 199-207.
12. Dietze P, Jolley D, Fry C, Bammer G. Transient changes in behaviour lead to heroin overdose: results from a case-crossover study of non-fatal overdose. Addiction 2005; 100: 636-642.
13. Caplehorn JR, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health 2002; 26: 358-362.
14. Martyres RF, Clode D, Burns JM. Seeking drugs or seeking help? Escalating "doctor shopping" by young heroin users before fatal overdose. Med J Aust 2004; 180: 211-214.
15. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: summary of national findings. Rockville, Md: SAMHSA, 2011. (NSDUH Series H-41, HHS Publication No. (SMA) 11-4658.) http://www.samhsa.gov/data/nsduh/2k10nsduh/2k10results.htm (accessed Aug 2012).
16. Shand FL, Campbell G, Hall W, et al. Real-time monitoring of Schedule 8 medicines in Australia. Med J Aust 2013; 198: 80-81.
17. Nielsen S, Bruno R, Carruthers S, et al. Investigation of pharmaceutical misuse amongst drug treatment clients. Melbourne: Turning Point Alcohol and Drug Centre, 2008.
18. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005; 6: 107-112.
19. Royal Australasian College of Physicians. Prescription opioid policy: improving management of chronic non-malignant pain and prevention of problems associated with prescription opioid use. Sydney: RACP, 2009.
20. Ernst E, Bartu A, Popescu A, et al. Methadone-related deaths in Western Australia 1993-99. Aust N Z J Public Health 2002; 26: 364-370.
21. Fountain J, Griffiths P, Farrell M, et al. Benzodiazepines in polydrug-using repertoires: the impact of the decreased availability of temazepam gel-filled capsules. Drugs Educ Prev Policy 1999; 6: 61-69.
22. Shand F, Topp L, Darke S, et al. The monitoring of drug trends in Australia. Drug Alcohol Rev 2003; 22: 61-72.
23. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253-263.
24. Darke S, Ross J, Teesson M, Lynskey M. Health service utilization and benzodiazepine use among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2003; 98: 1129-1135.